Yarrow Bioscience (YARW) Divestments (2022 - 2023)
Yarrow Bioscience's (YARW) quarterly Divestments came in at $5.0 million in Q1 2023, down 68.26% YoY from $15.8 million in Q1 2022, and up 499900.0% on a QoQ basis from $1000.0 in Q4 2022.
Yarrow Bioscience (YARW) Divestments (2022 - 2023) Analysis & Trends
Yarrow Bioscience (YARW) has 2 years of Divestments data on file, last reported at $5.0 million in Q1 2023.
- Quarterly Divestments fell 68.26% year-over-year to $5.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $5.0 million (down 68.09% YoY) and the FY2023 annual result came in at $5.0 million, down 68.09% from the prior year.
- Divestments improved to $5.0 million in Q1 2023, from $1000.0 in the prior quarter.
- In the past five years, Divestments ranged from a high of $15.8 million in Q1 2022 to a low of -$86000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -13.21 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -86,000.00 |
| Mar 31, 2022 | 15.75 Mn |